KLRB1 and rheumatoid arthritis: Newly diagnosed RA patients were assessed at baseline (before start of MTX treatment) and at 3 and 6 months after start of treatment for absolute numbers of circulating CD4+CD161+ T-cells and for clinical parameters of disease activity.